Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
Mitton-Fry, M.J., Arcari, J.T., Brown, M.F., Casavant, J.M., Finegan, S.M., Flanagan, M.E., Gao, H., George, D.M., Gerstenberger, B.S., Han, S., Hardink, J.R., Harris, T.M., Hoang, T., Huband, M.D., Irvine, R., Lall, M.S., Megan Lemmon, M., Li, C., Lin, J., McCurdy, S.P., Mueller, J.P., Mullins, L., Niosi, M., Noe, M.C., Pattavina, D., Penzien, J., Plummer, M.S., Risley, H., Schuff, B.P., Shanmugasundaram, V., Starr, J.T., Sun, J., Winton, J., Young, J.A.(2012) Bioorg Med Chem Lett 22: 5989-5994
- PubMed: 22892121
- DOI: https://doi.org/10.1016/j.bmcl.2012.07.005
- Primary Citation of Related Structures:
4FSF - PubMed Abstract:
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described.
Organizational Affiliation:
Medicinal Chemistry, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA.